View in EDS

A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.

Saved in:
Bibliographic Details
Title: A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.
Authors: Ott HM; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Graves AP; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania., Pappalardi MB; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Huddleston M; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania., Halsey WS; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania., Hughes AM; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania., Groy A; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Dul E; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania., Jiang Y; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania., Bai Y; Molecular Medicine Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Annan R; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania., Verma SK; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Knight SD; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Kruger RG; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Dhanak D; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Schwartz B; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania., Tummino PJ; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., Creasy CL; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania. Molecular Medicine Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania., McCabe MT; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania. michael.t.mccabe@gsk.com.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2014 Dec; Vol. 13 (12), pp. 3062-73. Date of Electronic Publication: 2014 Sep 24.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 25253781
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ott+HM%22">Ott HM</searchLink>; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Graves+AP%22">Graves AP</searchLink>; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Pappalardi+MB%22">Pappalardi MB</searchLink>; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Huddleston+M%22">Huddleston M</searchLink>; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Halsey+WS%22">Halsey WS</searchLink>; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Hughes+AM%22">Hughes AM</searchLink>; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Groy+A%22">Groy A</searchLink>; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Dul+E%22">Dul E</searchLink>; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Jiang+Y%22">Jiang Y</searchLink>; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Bai+Y%22">Bai Y</searchLink>; Molecular Medicine Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Annan+R%22">Annan R</searchLink>; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Verma+SK%22">Verma SK</searchLink>; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Knight+SD%22">Knight SD</searchLink>; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Kruger+RG%22">Kruger RG</searchLink>; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Dhanak+D%22">Dhanak D</searchLink>; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Schwartz+B%22">Schwartz B</searchLink>; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Tummino+PJ%22">Tummino PJ</searchLink>; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Creasy+CL%22">Creasy CL</searchLink>; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania. Molecular Medicine Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22McCabe+MT%22">McCabe MT</searchLink>; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania. michael.t.mccabe@gsk.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101132535%22">Molecular cancer therapeutics</searchLink> [Mol Cancer Ther] 2014 Dec; Vol. 13 (12), pp. 3062-73. <i>Date of Electronic Publication: </i>2014 Sep 24.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%2C+Inc%22">American Association for Cancer Research, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101132535 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1538-8514 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215357163%22">15357163 </searchLink><i>NLM ISO Abbreviation: </i>Mol Cancer Ther <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=25253781
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1535-7163.MCT-13-0876
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 3062
    Titles:
      – TitleFull: A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ott HM
      – PersonEntity:
          Name:
            NameFull: Graves AP
      – PersonEntity:
          Name:
            NameFull: Pappalardi MB
      – PersonEntity:
          Name:
            NameFull: Huddleston M
      – PersonEntity:
          Name:
            NameFull: Halsey WS
      – PersonEntity:
          Name:
            NameFull: Hughes AM
      – PersonEntity:
          Name:
            NameFull: Groy A
      – PersonEntity:
          Name:
            NameFull: Dul E
      – PersonEntity:
          Name:
            NameFull: Jiang Y
      – PersonEntity:
          Name:
            NameFull: Bai Y
      – PersonEntity:
          Name:
            NameFull: Annan R
      – PersonEntity:
          Name:
            NameFull: Verma SK
      – PersonEntity:
          Name:
            NameFull: Knight SD
      – PersonEntity:
          Name:
            NameFull: Kruger RG
      – PersonEntity:
          Name:
            NameFull: Dhanak D
      – PersonEntity:
          Name:
            NameFull: Schwartz B
      – PersonEntity:
          Name:
            NameFull: Tummino PJ
      – PersonEntity:
          Name:
            NameFull: Creasy CL
      – PersonEntity:
          Name:
            NameFull: McCabe MT
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2014 Dec
              Type: published
              Y: 2014
          Identifiers:
            – Type: issn-electronic
              Value: 1538-8514
          Numbering:
            – Type: volume
              Value: 13
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Molecular cancer therapeutics
              Type: main
ResultId 1